Acurx signals launch of pivotal recurrent CDI trial in H2 2026 while strengthening ibezapolstat pipeline (NASDAQ:ACXP)
Acurx Pharmaceuticals(US:ACXP) Seeking Alpha·2026-03-13 17:03Management View - Acurx Pharmaceuticals, Inc. (ACXP) reported a receipt of $1.4 million in gross proceeds from the execution of Series F Warrants in October 2025 [2] - The company is preparing to launch a pivotal recurrent CDI trial in the second half of 2026 while also strengthening its ibezapolstat pipeline [2]